🔎 Trials Near Me

Home › B-Cell Lymphoma › Colorado › Denver

Pag-aaral pangklinika para sa B-Cell Lymphoma sa Denver, CO

Isang pag-aaral para sa B-Cell Lymphoma ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Denver. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

Nagre-recruitPhase 1
  • Colorado Blood Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT07101328

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Nagre-recruitPhase 1/2
  • Colorado Blood Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT05826535

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

Nagre-recruitPhase 3
  • Colorado Blood Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

Nagre-recruitPhase 2
  • Colorado Blood Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 13, 2026 · NCT04792489

A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas

Nagre-recruitPhase 1/2
  • Colorado Blood Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 16, 2026 · NCT05463263

SynKIR-310 for Relapsed/Refractory B-NHL

Nagre-recruitPhase 1
  • Colorado Blood Cancer Institute, part of Sarah Cannon Cancer Institute, Denver
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 14, 2026 · NCT06544265

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Nagre-recruitPhase 1
  • Children's Hospital Colorado, Denver
Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Pag-aaral para sa B-Cell Lymphoma sa ibang lungsod

Iba pang pag-aaral sa Denver

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.